On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when the results of other, larger clinical trials become available. This approval is based on the favourable recommendation issued by the…
The Horizon Europe funded project ASCERTAIN invites you to the webinar “How do different countries make decisions on reimbursing new medicines?” The webinar will take place on Wednesday 2nd April 2025, from 16:00 to 17:30 CET. The webinar will be given by Tom Belleman, PhD candidate at the Erasmus School of Health Policy and Management…
On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…
My name is Maureen , and I was diagnosed with Myeloma in 2017 at the age of 55 and was fortunate to have been invited to join a clinical trial. This was successful and my myeloma is currently in remission and being monitored. My diagnosis was life-changing, but I refuse to let myeloma define me. The…
My name is Ritva, and I live in Finland. I got my myeloma diagnosis four and a half years ago, when I was 63 years old. The first days after the diagnosis, I thought this is only a bad dream, but I had to accept the fact that myeloma was now part of my life.…
My name is Ariunsanaa and last year my mother was diagnosed with myeloma. At that time, both my sibling and I were living abroad. We soon realised there was no available treatment in our hometown, so we made the difficult decision to move her to an overseas location where she could receive proper care. Hearing…
My name is Wouter, I am living in The Netherlands, and I am 55 years old. In March 2024, I was diagnosed with myeloma, which turned my world upside down. One of the biggest challenges I faced was the physical pain caused by my broken vertebrae. Learning to manage that pain while also coming to…
Among the biggest policy initiatives targeting cancer at the European Union (EU) level, Europe’s Beating Cancer Plan is one of the most important and ambitious. Launched in 2021, it set to “tackle the entire disease pathway, from prevention to quality of life of cancer patients and survivors”. On 4 February 2025 the European Commission published…
